Biocon Ltd., India's largest biotechnology company, released preliminary data from a recently concluded clinical study conducted in India, on IN-105, its novel oral insulin candidate for the treatment of diabetes.
The study included 264 patients poorly controlled on metformin, who were randomly chosen receive either IN-105 or placebo...